Loading...

Systemic treatment for metastatic prostate cancer

The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...

Full description

Saved in:
Bibliographic Details
Published in:Asian J Urol
Main Author: Gravis, Gwenaelle
Format: Artigo
Language:Inglês
Published: Second Military Medical University 2019
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/
https://ncbi.nlm.nih.gov/pubmed/31061802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002
Tags: Add Tag
No Tags, Be the first to tag this record!